NEW YORK--(BUSINESS WIRE)---- $TLX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix†or the "Company†) (NASDAQ: TLX) and reminds investors of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia ...

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Telix Pharmaceuticals Ltd. securities for the period between February 21, 2025, and August 28, 2025, due to alleged misleading statements made by the company regarding its business and operations [1][5]. Group 1: Lawsuit Details - The lawsuit claims that defendants made materially false and misleading statements about Telix's progress in prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. - Investors who purchased Telix securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by January 9, 2026, to represent other class members in the litigation [1][3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited and certain officers for alleged violations of federal securities laws during the specified class period [1][2]. Group 1: Class Action Details - The lawsuit seeks to recover damages for all individuals and entities that purchased or acquired Telix securities between February 21, 2025, and August 28, 2025 [2]. - The complaint alleges that the defendants made false and misleading statements regarding Telix's progress in prostate cancer therapeutic candidates, the quality of its supply chain, and the overall business prospects [3]. Group 2: Next Steps and Participation - Investors who suffered losses in Telix have until January 9, 2026, to request to be appointed as lead plaintiff in the case [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Telix Pharmaceuticals Ltd. securities during the specified Class Period, highlighting potential misstatements and misleading information from the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Telix Pharmaceuticals Ltd. securities purchased between February 21, 2025, and August 28, 2025 [1]. - The lawsuit alleges that defendants made materially false and misleading statements regarding the progress of Telix's prostate cancer therapeutic candidates and the quality of its supply chain [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by January 9, 2026, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its leadership in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - The Telix Pharmaceuticals class action lawsuit alleges that the company and its executives made misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain, leading to significant stock price declines following negative disclosures [3][4][5]. Group 1: Lawsuit Details - The class action lawsuit seeks to represent purchasers of Telix Pharmaceuticals Ltd. securities from February 21, 2025, to August 28, 2025 [1]. - The lawsuit is titled Thomas v. Telix Pharmaceuticals Ltd., No. 25-cv-02299 (S.D. Ind.) and charges the company with violations of the Securities Exchange Act of 1934 [1][2]. Group 2: Allegations - The lawsuit alleges that Telix Pharmaceuticals materially overstated its progress in developing prostate cancer therapeutics and the quality of its supply chain [3]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, which led to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [4]. - On August 28, 2025, Telix revealed it received a Complete Response Letter from the FDA regarding its product TLX250-CDx, which identified deficiencies in its Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in its ADS price over two trading sessions [5]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Telix Pharmaceuticals securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Telix Pharmaceuticals Ltd. securities between February 21, 2025, and August 28, 2025, alleging that the company made materially false and misleading statements regarding its business and operations [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Telix's defendants overstated the progress made with prostate cancer therapeutic candidates and the quality of its supply chain and partners [5]. - Investors are entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by January 9, 2026, to represent other class members in the litigation [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing investor rights [4].

Core Viewpoint - Telix Pharmaceuticals Limited is facing a class action lawsuit for securities fraud, with allegations of false and misleading statements regarding its therapeutic candidates and supply chain quality [5]. Summary by Sections Class Action Lawsuit - The Schall Law Firm is reminding investors of a class action lawsuit against Telix Pharmaceuticals for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Telix securities between February 21, 2025, and August 28, 2025, are encouraged to contact the firm before January 9, 2026 [2]. Allegations - The complaint alleges that Telix overstated its progress with therapeutic candidates for prostate cancer and inflated the quality of its supply chain [5]. - The company's public statements were deemed false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [5].

Core Viewpoint - The Telix Pharmaceuticals class action lawsuit alleges that the company and its executives made false statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain, leading to significant stock price declines following negative disclosures [4][5][6]. Company Overview - Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals [3]. Allegations of the Lawsuit - The lawsuit claims that during the Class Period, Telix Pharmaceuticals materially overstated its progress in developing prostate cancer therapeutics and the quality of its supply chain [4]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission regarding its disclosures on prostate cancer therapeutics, resulting in a more than 13% drop in its stock price over two trading sessions [5]. - On August 28, 2025, Telix revealed it received a Complete Response Letter from the FDA for its product TLX250-CDx, citing deficiencies in the Chemistry, Manufacturing, and Controls package, which led to a more than 21% decline in its stock price over two trading sessions [6]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Telix Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the class action lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [8]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [8].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period†). The lawsuit seeks to recover damages for Telix investors under the federal securities laws. To join the Telix class action, go to https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim. ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Actions and Investigations - Shareholders who purchased Telix securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission regarding disclosures related to its prostate cancer therapeutic candidates, leading to a 10.44% drop in the price of Telix's American Depositary Shares on July 23, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4].